MIB Agents OsteoBites and osTEAo

Turning a promising research idea into a treatment for children with osteosarcoma requires early investment, collaboration among researchers and funders, and years of work to move breakthroughs from the lab to the clinic. In this episode, Dr. Ryan Roberts of Nationwide Children's Hospital, along with representatives from CancerFree KIDS and MIB Agents, will walk through the lifecycle of pediat...

This presentation will give a high-level overview of the role genetic counselors play in a healthcare team. We will review general information about cancer genetics, including some of the different ways genetic testing is used in the oncology setting. Amy Daly is a board-certified genetic counselor with 20 years of experience providing individuals, families, and their healthcare providers support...

In this special Halloween episode of osTEAo, Sammy, Inaaya, Elise, Camille, and Sabina share some of the scariest and most unexpected moments of their osteosarcoma journeys. From unexpected side effects to frightening experiences during treatment, OsteoWarriors reflect on the challenges that can catch you off guard and the moments that stay with you long after treatment ends. Tune in for an honest...

Dr. Michelle Choe will introduce a phase 1 clinical trial currently open at Fred Hutch Cancer Center for folate receptor alpha (FOLR1)-CAR T cells for pediatric and adult patients with relapsed/refractory osteosarcoma after front-line therapy. This clinical trial is currently actively accruing and treating patients. The primary objective of the study is to evaluate the safety and tolerability of F...

There is an urgent need for safe and effective therapies to improve outcomes for patients with relapsed osteosarcoma. Viscum album extract (Iscador P, Iscador AG, Arlesheim, Switzerland) is a mistletoe extract manufactured from the leaves, stems and berries of Viscum album L., grown on pine trees (P = Pini). It has shown efficacy and safety in lab experiments and small clinical trials for patients...

This month on osTEAo, Sammy, Inaaya, Mackenzie, and Keely discuss Childhood Cancer Awareness Month, how childhood cancer is portrayed and understood, and what those portrayals can miss about the realities of a cancer diagnosis. They share personal experiences and perspectives on awareness, treatment, advocacy, and the different ways patients, siblings, and families experience childhood cancer. The...

Osteosarcoma Webinar Series: W. Thomas Cash, MD, MSc Children's Healthcare of Atlanta will discuss his work the TIGER study, which is a phase 1 study testing the TBL1 inhibitor tegavivint in combination with gemcitabine for pediatric and AYA patients with relapsed or refractory osteosarcoma. The topic of this presentation is the TIGER study, which is a phase 1 study testing the TBL1 inhibitor...

Osteosarcoma Webinar Series: Subhashini Jagu, PhD, from the National Cancer Institute, joins us on OsteoBites to discuss the Childhood Cancer Data Initiative. This presentation highlights how the Childhood Cancer Data Initiative (CCDI) Data Ecosystem is transforming pediatric cancer research by making diverse biomedical data more accessible, interoperable, and reusable. Attendees will learn how th...

The Greenfield Lab’s long-standing research interests focus on basic and translational aspects of bone biology, and on osteosarcoma metastasis. The osteosarcoma project aims to repurpose FDA-approved drugs to block growth of lung metastases, which is the primary cause of lethality in osteosarcoma patients. Current studies utilize 3D sarcosphere cultures and mouse models. Dr. Greenfield earned his...

This episode of osTEAo features OsteoWarriors Inaaya, Sloane, and Elise sharing their experiences adapting summer activities and travel with limb differences. They discuss everything from summer camp, swimming, and ziplining to navigating theaters, airports, and public transportation. The conversation also explores accessibility, disability rights, advocating for accommodations, and finding new wa...

Metastatic osteosarcoma remains a major clinical challenge, highlighting the need to better understand the molecular mechanisms that drive disease progression. In this talk, Moreno will present the use of an in vivo CRISPR interference (CRISPRi) screen to identify genes that promote osteosarcoma progression. She will focus on KLF5, a transcription factor that emerged as a key regulator in our stud...

Dr. Alexander Davies discusses his OutSmarting Osteosarcoma-funded work on the validation of MCL1 inhibition and combinatorial therapy for elimination of osteosarcoma lung metastasis, funded Because of Matthew, in partnership with Fishin' for the Cure.

Osteosarcoma Webinar Series: Jeremy Rosenblum, MD from New York Medical College will discuss his work on combinational next generation CAR NK immunotherapy in osteosarcoma. Immunotherapeutic approaches to treating osteosarcoma have had limited success to date. Using natural killer cells as the base platform, our group seeks to combine immunotherapies to cure osteosarcoma. The presentation will des...

Osteosarcoma Webinar Series: Dr. Jing Huang is a Senior Investigator and Head of the Cancer and Stem Cell Epigenetics Group in the Laboratory of Cancer Biology and Genetics at the National Cancer Institute (NCI). He received his bachelor’s degree in Biochemistry from Peking University and his Ph. D. in Biochemistry and Biophysics from the University of Rochester, followed by postdoctoral training...

Recorded live at FACTOR 2026, this episode of osTEAo features conversations with OsteoWarriors, OsteoSiblings, parents and family members, as well as the behind-the-scenes volunteers and staff who help make FACTOR possible. Guests share their experiences, favorite memories, and what this community means to them, offering a glimpse into the connection, support, and sense of belonging that define th...

In this episode of osTEAo, Sammy and Inaaya are joined by Elise, Sloane, and Camille for a conversation about self-advocacy and how it evolves after an osteosarcoma diagnosis. The group shares personal experiences navigating college, careers, travel, accessibility, and everyday life as survivors and individuals with disabilities. From campus accommodations to airport encounters, they discuss the c...

Osteosarcoma Webinar Series: Barbara VanHare from the Rare Cancer Research Foundation will discuss the key role patients can play in accelerating Osteosarcoma breakthroughs through the donation of excess tissue and clinical data. She will walk through current barriers in rare cancer research, why each patient's story and tissue is important and cover the different ways to participate, all at n...

Matteo Trucco, MD, joins us on OsteoBites to break down the scientific panels featured at the 2026 FACTOR conference. From clinical trials to the latest advances in osteosarcoma research, Dr. Trucco will guide attendees through the key themes and conversations shaping FACTOR 2026. Whether you are attending FACTOR for the first time or returning for another year, this preview is a great way to feel...

In this episode of osTEAo, OsteoWarriors share honest and personal reflections on the mental health challenges that can come with diagnosis, treatment, surgery, and survivorship. They talk about the fear, isolation, and loss of normalcy that often come with cancer, especially as young people trying to navigate school, relationships, identity, and everyday life at the same time. From struggling to...

David Shulman, MD, joins us on OsteoBites to discuss the newly opened phase 1/2 study to evaluate LNTH-2403, a LRRC15-targeted radiopharmaceutical, in patients with relapsed/refractory osteosarcoma. For many years, LRRC15 has been known to be an important target in osteosarcoma. A prior study showed a strong signal of activity of an LRRC15-targeted therapy in osteosarcoma; however, the development...

Andrew Clugston, PhD, a postdoctoral fellow in the Sweet-Cordero Lab at UCSF joins us on OsteoBites to discuss his OutSmarting Osteosarcoma funded work, in partnership with the RISE Foundation, on defining tumor-specific vulnerabilities by mapping oncogenic structural variation in osteosarcoma. The genomes of osteosarcoma (OS) cancer cells are among the most complex cancer genomes ever observed. I...

OsteoBites welcomes Caroline Maloney, MD, PhD, from the Medical College of Wisconsin, who will discuss her research on surgery-accelerated metastasis and developing perioperative therapies. Pulmonary metastasis remains the major cause of death in osteosarcoma. The timing of metastatic relapse defines clinically meaningful subgroups in osteosarcoma with patients who relapse within 6–12 months of su...

In this episode of osTEAo, the group explores how music is a powerful tool for coping with cancer - helping patients process emotions, find comfort during treatment, and stay connected to themselves and others. From meaningful song interpretations to personal stories of healing, the conversation highlights the impact of music. The episode also features a heartfelt farewell to co-host Mia as she re...

Philippos A. Costa, MD joins us on OsteoBites to introduce a Phase 2 clinical trial of zanzalintinib for people with osteosarcoma. The study is intended for patients who cannot receive standard chemotherapy or whose cancer has not responded to available treatments. The goal is to explore whether this therapy can control the disease while preserving quality of life during treatment. Philippos A. Co...

The Rao Lab at Seattle Children's Research Institute developed a three-dimensional (3D) tissue-engineered model of osteosarcoma to investigate the effects of the extracellular matrix on malignant cell function. The study demonstrated that culturing osteosarcoma (OS) cells within a 3D collagen matrix induced unique cellular responses, altered morphology, enhanced tumorigenic behavior, and reduc...